New preprint · November 2026 · PATRE SYNGAP1

Where a variant lies in SYNGAP1 matters for speech

Why do some children with SYNGAP1 learn to talk in sentences while others use only a few words? Using data from 334 participants of the PATRE registry, we found that the type of variant and where it lies in the SynGAP protein are linked to language development. This may help to plan upcoming clinical trials more precisely.

334 participants with a genetic report79 missense255 truncating / splicing
The key finding

Two genetic groups stand out

7%of people with a missense variant in the C2 domain had learned to speak in two-word phrases (2 of 28), compared with 52% of people with missense variants elsewhere.
62%of people with a truncating variant in the PH domain had learned two-word phrases (50 people), compared with 32% of people with truncating variants elsewhere.
Background in a nutshell

SynGAP: one protein, several parts

The SYNGAP1 gene is the blueprint for the SynGAP protein, which helps nerve cells adjust their connections (synapses). Like a tool with a handle, a hinge and a blade, the protein has several parts, called domains, each with its own job. Most people with SYNGAP1 have less working SynGAP protein (“haploinsufficiency”). Our data show that this is not the whole story.

The SynGAP protein and its domains

The two regions highlighted in our study
N-termPHC2RasGAPPost-GAPC-terminal regionC2 + missensespeech more affectedPH + truncatingspeech more often preservedstart of the proteinend (amino acid 1343)

Two kinds of genetic variants

The protein is built from a chain of building blocks (amino acids)
Typical proteinMissense variantone building block is swapped: the protein is made, but changedTruncating / splicing variantthe instruction stops early: often little or no protein from this copy
The results

How language develops in each group

Learning to speak in two-word phrases

About how many out of 10 people
Missense · C2 domain7%Missense · other domains52%Truncating · PH domain62%Truncating · other domains32%Share who have learned to speak in two-word phrases (shown as “out of 10 people”).

Current spoken language

Five levels, from no words to age-appropriate language
1No understandable words2A few single words (up to 50)3Many single words, simple two-word phrases4Simple sentences, not yet age-appropriate5Age-appropriate languageC2 missenseother missensePH truncatingDots show the typical (median) level in each group. Other truncating variants: also level 2.
C2 missense variants: markedly poorer spoken language and everyday communication, also after taking age into account. Truncating variants in the same C2 region did not show this pattern.
PH truncating variants: spoken language was more often preserved. This does not mean a generally milder form of SYNGAP1; we only looked at language and communication.
RasGAP domain: no clear difference in language for either variant type.
What does this mean?

Questions families often ask

Can this predict how my child will speak?

No. Children within each group differ a lot, and this was a snapshot in time. The results describe groups, not individual children.

Why could C2 missense variants behave differently?

A missense variant produces a changed protein rather than less protein. Computer models from other research groups suggest that changes in the C2 domain can disturb how SynGAP works with its partners Ras and Rap and with the cell membrane. This still has to be confirmed in the lab.

What does this mean for clinical trials?

Antisense oligonucleotides (ASOs), which aim to increase the amount of working SynGAP, are approaching clinical trials. Knowing that genetic subgroups start from different language levels helps to build balanced study groups, choose suitable outcomes and interpret results fairly. Whether subgroups respond differently to treatment is not yet known.

Why your genetic report matters

Only 28 people had a C2 missense variant

Findings like these are only possible because families uploaded their child’s genetic report to the PATRE registry. Some protein regions were represented by just 3 to 6 people, too few for firm conclusions. Every additional family, and every uploaded genetic report, brings us closer to answers.

About the study

Beyond Haploinsufficiency: Protein Domain and Variant Class Shape Language Outcomes in SYNGAP1-DEE. medRxiv preprint, November 2026. doi.org/10.64898/2026.11.04.26367250

L. Kiwull, V. Schmeder, M. Zenker, M. Mengual Hinojosa, G. Kluger, K. Eschermann · Paracelsus Medical University (EURAS Project), Salzburg · Otto-von-Guericke University Magdeburg · SYNGAP Elternhilfe e.V. · Funded by the European Union (Horizon Europe, EURAS, Grant No. 101080580).

Thank you to all families who share their experience in the PATRE registry, and to SYNGAP Elternhilfe e.V. and the SYNGAP1 patient organizations for their support.

This preprint has not yet been peer-reviewed and should not be used to guide clinical practice. Findings are based on caregiver-reported registry data linked to genetic reports.

Congress report · October 2026

One week, two congresses, one mission: better therapies

In October, our team presented new findings from the PATRE and PATRAS registries at two major European meetings. A central question: is the severity of autism-related behavior in SYNGAP1 driven by how often seizures occur? Our data suggest it is not.

Rome · 12–13 Oct→Thessaloniki · 16–17 Oct
Overview: Rome and Thessaloniki congresses, October 2026
Our SYNGAP1 take-home · PATRE registry

Autism severity ≠ seizure frequency

522SYNGAP1 participants in the registry, 337 with complete epilepsy and behavior data
10 / 10seizure types: no detectable link between peak seizure frequency and autism-related behavior
Atypical absencesshowed the strongest link with autism-related behavior, pointing to shared thalamocortical circuits
ROME · 12–13 OCTOBER

10th International Meeting on Rare Disorders of the RAS-MAPK Pathway

We thank ERN-ITHACA, the SEDRA Foundation and the Scientific Board (Marco Tartaglia, Alain Verloes, Emma Burkitt-Wright and Martin Zenker) for an excellent meeting. The discussions gave important directions for our ongoing work on SYNGAP1 and the RASopathies.

EURAS and PATRAS registry data. Anna Fejtová presented the latest data from EURAS and PATRAS, highlighting the strong growth of the registries.
Patient-specific SYNGAP1 research. An inspiring exchange with Bernadette Basilico on her research; we look forward to working together.
EURAS: EU-funded 2023–2027initiated by parents14 partners · 8 countries
Diagram of the RAS-MAPK pathway
SYNGAP1 regulates RAS, the starting point of the RAS-MAPK pathway shared by the RASopathies.
Anna Fejtová presenting the EURAS consortium
EURAS: patient research partnership
Presentation of first SYNGAP1 phenotype analysis
First phenotype analysis: autism severity and epilepsy
Evening view over Rome
Rome by night
THESSALONIKI · 16–17 OCTOBER

9th EPNS Research Meeting

We thank the European Paediatric Neurology Society (EPNS) and our local hosts, Dimitrios Zafeiriou and Pinelopi Dragoumi, for a constructive research meeting, and the chairs of the Fetal & Neonatal Neurology Working Group, Regina Trollmann, Lucia Gerstl and Agnese Suppiej, for their invitation and the scientific discussion.

Clinical findings from the PATRE registry

Of 522 SYNGAP1 participants, 337 had completed both the epilepsy and the behavior questionnaire. Caregiver-reported autism-related behavior showed no correlation with peak seizure frequency in any of 10 seizure types. Atypical absences stood out, suggesting a role of shared thalamocortical circuits.

Thalamic circuits. Željka Rogač gave a compelling talk on sleep spindles. Sleep spindles are generated in the thalamic reticular nucleus, the same circuitry highlighted by our registry data.
Synaptic vulnerability. Thank you to Juliana Ribeiro Constante for constructive discussions about the “Synaptic Vulnerability Continuum” in SYNGAP1.
Read the preprint
Presentation of PATRE registry data at the EPNS Research Meeting
Redefining clinical endpoints in SYNGAP1-DEE via the PATRE registry
Slide: no association between peak seizure frequency and autism severity across 10 seizure types
Result 1: no detectable association between peak seizure frequency and caregiver-reported autistic behavior across all 10 seizure types.
Evening exchange at the EPNS Research Meeting
Evening exchange at EPNS
Thessaloniki coastline
Thessaloniki waterfront
Official poster of the 9th EPNS Research Meeting
9th EPNS Research Meeting 2026
Core conclusion

Seizure control alone is not enough

Our key takeaway from both meetings: for people with SYNGAP1, prioritizing seizure control alone is insufficient. Precision therapies must target the neuronal circuits underlying cognition and behavior. This requires growing clinical registries and continued collaboration with families and research partners across Europe.

Thank you

Our deepest gratitude goes to every family affected by SYNGAP1 and RASopathies who contributes to the PATRE and PATRAS registries. This work would not be possible without the foundational work of SYNGAP Elternhilfe e.V. (led by Verena Schmeder and Marcos Mengual Hinojosa) and the EURAS project.

EURAS ProjectSYNGAP Elternhilfe e.V.Syngap1 EspañaSyngap1 ArgentinaCure Syngap1 LATAMCURE SYNGAP1 USNoonan RASopathies Network USAParacelsus Medical UniversityOtto-von-Guericke-Universität Magdeburg

The preprint has not yet been peer-reviewed. Findings are based on caregiver-reported registry data.

New Preprint Release: Investigating the Link Between Seizure Frequency and Autistic Behavior in SYNGAP1

Recently, a new large-scale preprint utilizing data from the PATRE registry (N=337) was published, addressing a long-standing question in the study of developmental and epileptic encephalopathies (DEEs).

Historically, a prevailing clinical assumption suggested that the severity of behavioral challenges in epilepsy patients was directly proportional to how often seizures occurred. While the medical and research communities have recently begun to suspect that this connection might not hold true for DEEs, large-scale empirical data to support this shift in thinking has been lacking.

Our latest publication finally provides the necessary data for SYNGAP1, revealing two crucial clinical takeaways:

  • Autism Severity is Independent of Seizure Frequency: Our analysis demonstrates that caregiver-reported autism severity is entirely independent of the maximum caregiver-reported seizure frequency. This finding highlights that the neurodevelopmental burden in SYNGAP1 is highly complex and extends far beyond the simple quantitative counting of seizures.
  • Atypical Absences as a Clinical Marker: The data suggests that qualitative factors play a highly significant role. Specifically, the presence—rather than the frequency—of caregiver-reported atypical absences serves as a critical clinical marker associated with higher caregiver-reported autistic behaviors (FDR-adjusted p = 0.001).

The Power of the PATRE Registry

Milestones in DEE research like this are only possible through the dedication of our community. Your willingness to share your daily realities via the PATRE registry is what drives these medical breakthroughs forward.

We extend our deepest gratitude to all participating patients, parents, families, and advocacy organizations. Special thanks to SYNGAP Elternhilfe e.V. & Syngap Global Network (SGN).

We also thank the EURAS Project consortium and all contributing co-authors across Europe.

Read the full preprint here: https://www.medrxiv.org/content/10.64898/2026.04.19.26351217v1

Poster at IEC 2025 Lisbon

Empowering Patients in Research – First Insights from 444 Participants in the PATRE SYNGAP1 Registry

We are proud to share that our work on the PATRE SYNGAP1 Registry was presented at the International Epilepsy Congress (IEC) 2025 in Lisbon.

Our poster, presented by Kirsten Eschermann, was selected for the prestigious ILAE YES (Young Epilepsy Section) Poster Tour – Poster #363.

Why this matters

The PATRE SYNGAP1 Registry was created together with families, clinicians, and researchers as part of the EURAS Horizon Europe consortium. It is a multilingual, app-based platform that empowers families to directly contribute health information and experiences. This data helps researchers understand SYNGAP1-related encephalopathy and accelerates the path towards new therapies.

Key results from 444 SYNGAP1 participants

🔹 Developmental milestones are consistently delayed:

  • Sitting unsupported: ~12 months
  • Walking independently: ~28 months
  • First two-word sentences: ~47 months

🔹 Functional outcomes (PEDI-CAT):

  • Daily activities & Social/Cognitive: ~4th percentile
  • Mobility: ~12th percentile

🔹 HPO-based phenotyping (systematic clinical feature mapping):

  • High frequency of neurodevelopmental features (motor delay, speech delay, autistic behaviors)
  • Frequent epilepsy-related phenotypes (generalized motor & non-motor seizures, absence seizures, myoclonic-atonic seizures)
  • Behavioral and sensory features (hyperactivity, self-injury, abnormal pain sensation, sleep disturbance)
  • Comorbidities including vision problems, scoliosis, growth abnormalities

This comprehensive HPO dataset provides one of the most detailed phenotypic landscapes of SYNGAP1 to date, demonstrating the power of structured, patient-driven data collection.

Looking ahead

The PATRE platform is designed to be a model for rare epilepsies and neurodevelopmental disorders. By combining patient engagement with standardized data elements, we are building a resource that will:

  • Support preclinical models and therapeutic development
  • Enable international collaboration across research groups
  • Provide families with a stronger voice in research

PATRE Abstract Wins Mac Keith Press Best Abstract Award at EACD/IAACD 2025

We are delighted to share that our abstract

“Empowering Patients in Research: Insights from the World’s Largest SYNGAP1 Registry”

has been awarded the Mac Keith Press Best Abstract Award 2025 at this year’s EACD/IAACD Congress in Heidelberg.

This prestigious award honors the highest-rated abstract of the entire congress. With over 1,200 abstracts submitted from more than 80 countries, the selection process is highly competitive. The jury—appointed by Mac Keith Press, the nonprofit publisher of Developmental Medicine & Child Neurology—evaluates submissions based on originality, methodological quality, clinical relevance, and clarity of presentation. Our abstract was selected as the top submission of 2025.

The EACD/IAACD Congress is the world’s largest interdisciplinary conference on childhood disability. Held only every three years in cooperation with the International Alliance of Academies of Childhood Disability (IAACD), the event brings together clinicians, researchers, therapists, and family advocates from across the globe.

The award-winning abstract highlights the patient-centered approach of the SYNGAP1 Registry and its integration into PATRE and the EURAS project, showcasing how families’ active participation can drive scientific discovery in rare diseases.

We accepted the award on behalf of the entire team – but this recognition belongs to all collaborators who contributed their trust, time, and expertise to this shared effort.

A special thank you goes to the many SYNGAP1 families whose commitment made this research possible in the first place.

📎 Read also the official announcement on the EURAS website:

👉 www.euras-project.eu/news-events

EURAS

PATRE is very proud to have co-initiated the HORIZON EUROPE consortium EURAS.

PATRE is responsible for the patient registries in the consortium together with the University of Magdeburg.

Here is the link to a press release (in German).

This image has an empty alt attribute; its file name is euras_eu.png